20 episodes

From the Burgundy Chairs is a podcast for health system leaders created by Santis Health. Bringing you insight, understanding, and thoughtful discussion on issues affecting Canada’s health system, From the Burgundy Chairs will take you beyond the immediacy of the daily news cycle to untangle some of the health sector’s most intractable problems.

From the Burgundy Chairs Santis Health

    • News
    • 5.0 • 4 Ratings

From the Burgundy Chairs is a podcast for health system leaders created by Santis Health. Bringing you insight, understanding, and thoughtful discussion on issues affecting Canada’s health system, From the Burgundy Chairs will take you beyond the immediacy of the daily news cycle to untangle some of the health sector’s most intractable problems.

    Episode 20: The Future of Research, Advocacy and Care for the Parkinson’s Community

    Episode 20: The Future of Research, Advocacy and Care for the Parkinson’s Community

    With April being Parkinson’s Awareness Month, and April 11 being World Parkinson’s Day, Parkinson Canada is sharing the story of the “Why”; why Parkinson’s continues to be so prominent in Canada. Parkinson Canada is also sharing the “How”, exploring the four pillars of support Parkinson Canada provides, including funding critical research, providing support programs and resources, advocating alongside people living with Parkinson’s, and building awareness for the disease.
     
    In this episode, Caroline Pitfield is joined by Karen Lee, Parkinson Canada President and CEO, Dr. Tony Lang, Movement Disorder Specialist, and Liz Loewen, a member of the Parkinson Advisory Council who also lives with Parkinson’s.

    • 32 min
    Episode 19: Rute Fernandes on What we Need in Canada to Have a Successful Rare Disease Strategy

    Episode 19: Rute Fernandes on What we Need in Canada to Have a Successful Rare Disease Strategy

    Canadians rightfully ask why it takes so long to access new, innovative medicines. Government’s ability to review, approve and regulate the marketing of drugs is a robust, complex process. This is particularly true in Canada for people who need treatments for rare diseases, where access can vary based on where they are located in the country.


    While the federal government has spent the last two years focused on the COVID-19 response, one of Health Canada’s key policy objectives is to create a National Strategy for Drugs for Rare Diseases, and to decide on how to invest the $500 million a year that it set to flow in 2022.


    In this episode, Peter Cleary is joined by Rute Fernandes, General Manager of Takeda Canada, a pharmaceutical company that specializes in the development of rare disease medications. They discuss global best practices to develop better approaches to provide access to these critical medications, and what Canada can learn from other OECD countries and their rare disease drug strategies.

    • 24 min
    Episode 18: Bernard Lord on Reimagining Health Care to Improve the Wellbeing of Canadians

    Episode 18: Bernard Lord on Reimagining Health Care to Improve the Wellbeing of Canadians

    Across Canada, access to health care remains an ongoing challenge and the pressures within our system – aging population, chronic illness, hallway medicine and increased demand – have only been heightened by the COVID-19 pandemic.


    As health care continues to be debated in legislatures, virtual forums and at dinner tables across the country, we must ask hard questions and find ways to reimagine the way Canadians access health care services, programs and information.


    In this episode, Ross Wallace is joined by Bernard Lord, Chief Executive Officer of Medavie, a health solutions partner, to discuss innovative, collaborative, patient-focused approaches to health and care that help people stay healthy and in their homes as long as possible, help them navigate the health care system when they do need it and ultimately ensure they receive care at the right time and in the right place.


    --


    Bernard Lord is the Chief Executive Officer of Medavie.


    In his role, Bernard provides strategic leadership to further the organization’s mission to improve the wellbeing of Canadians. Previously, Bernard spent almost a decade on the Board of Medavie, served as President and CEO of the Canadian Wireless Telecommunication Association of Canada, and served as Premier of New Brunswick from 1999 to 2006. He sits on boards of several companies and organizations and, most recently, was appointed as chair of the International Federation of Health Plans.

    • 34 min
    Episode 17: Deborah Simon on the Health Human Resource Crisis

    Episode 17: Deborah Simon on the Health Human Resource Crisis

    Moving beyond COVID-19 will require a multi-faceted solution that involves government, the health care sector and the will of the Canadian population.  Pre-existing issues that have been amplified throughout the pandemic, including the health human resource crisis. Advocates have called on all levels of government to address the shortage of staff across the continuum of care. With time running out to train, recruit and retain staff to support the ageing population in Canada, solutions need to be actioned immediately.


     


    In this series, we discuss the impact of the pandemic on frontline health care workers, the programs that have attracted and/or caused staff to leave and solutions to this crisis as policy makers need to act immediately.


     


    Our first episode focuses on home and community care in Ontario. The Ontario Community Support Association (OCSA) represents over 220 not-for-profit organizations that provide a variety of health and wellness services to Ontarians. OCSA’s home and community care members have struggled throughout the pandemic pivoting to offering their services virtually.

    • 33 min
    Episode 16: Durhane Wong-Rieger on Canada’s Approach to a Rare Drugs Strategy

    Episode 16: Durhane Wong-Rieger on Canada’s Approach to a Rare Drugs Strategy

    Earlier this year, the Government of Canada began a public consultation on their 2019 commitment for a national strategy to address high-cost rare drugs. Now, almost seven months after the start of the public consultation and years after their initial commitment, there are few details on the strategy itself or how the government intends to invest $500 million per year set to begin in 2022. 
     
    In this episode, Peter Cleary, a Principal at Santis Health, spoke to President and CEO of the Canadian Organization for Rare Disorder (CORD), Durhane Wong-Rieger. They discussed CORD’s advocacy for a health care system that works for those with rare disorders, and the potential of Canada to position itself as a global leader in the rare disease space.

    • 22 min
    Episode 15: Suzanne McGurn on the Future of CADTH

    Episode 15: Suzanne McGurn on the Future of CADTH

    Vaccination numbers are rising and Canada is now emerging from the worst of the COVID-19 pandemic. This episode spotlights the Canadian Agency for Drugs and Technology in Health (CADTH) and how the organization is incorporating key lessons learned as it prepares to refresh its own strategy later this year.


    CADTH’s previous strategic plan covered the period of 2018-2021, but due to the all-consuming obligations of COVID-19, the Agency decided to postpone the creation and launch of a new plan by 12 months. CADTH is now in the early days of formulating and crystallizing new strategic priorities that will come into effect April 1, 2022.


    In this episode, Ross Wallace is joined by CADTH President & CEO Suzanne McGurn to discuss CADTH’s role during the pandemic, the Agency’s areas of future focus, global trends in health technology assessment – and their impact on Canada – and Suzanne's own insights after 12 months at the helm of the organization.

    • 39 min

Customer Reviews

5.0 out of 5
4 Ratings

4 Ratings

Top Podcasts In News

CBC Podcasts
The New York Times
CBC Podcasts
BBC World Service
The Daily Wire
The Globe and Mail